文献速递免疫规划传染病防控与疫情报告

日本医护人员接种两剂BNT162b2 mRNA疫苗后6个月内抗体滴度与细胞免疫的动态变化

Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
PubMed 文献 · Vaccine · 2022-06-17

本研究为前瞻性队列研究,纳入608名接种两剂BNT162b2疫苗的日本医护人员,随访6个月。结果显示抗体滴度在接种3周后升高,此后至研究结束持续下降,T细胞免疫应答呈相似动态。6名无基础疾病者核衣壳蛋白IgG由阴转阳,提示突破性感染,其中5例无症状。

要点

  • 接种两剂BNT162b2后6个月内,体液免疫与细胞免疫均减弱。
  • 608名参与者中6人出现突破性感染,其中5人无症状。
  • 抗体滴度于接种3周后升高,此后至研究结束持续下降。

核心结论

  • 接种BNT162b2疫苗后6个月内,体液免疫与细胞免疫均减弱;接种后6个月内无症状突破性感染发生率约为百分之一。

研究设计与样本

  • 前瞻性队列研究,6个月随访期,纳入日本医护人员,所有参与者均接种两剂BNT162b2疫苗。
  • 共608名参与者纳入分析,在接种前后多个时间点采集血清样本检测抗SARS-CoV-2抗体滴度与T细胞免疫应答。

主要发现

  • 抗体滴度在接种后3周升高,此后至研究结束期间下降。
  • T细胞免疫应答呈现与抗体相似的动态变化。
  • 6名无基础疾病参与者核衣壳蛋白IgG检测由阴转阳,提示突破性SARS-CoV-2感染,其中5例无症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The antibody titer is known to wane within months after receiving two doses of the Pfizer-BioNTech BNT162b2 mRNA SARS-CoV-2 vaccine. However, knowledge of the cellular immune response dynamics following vaccination is limited. This study to aimed to determine antibody and cellular immune responses following vaccination, and the incidence and determinants of breakthrough infection. METHODS: This prospective cohort study a 6-month follow-up period was conducted among Japanese healthcare workers. All participants received two doses of BNT162b2 vaccine. Anti-SARS-CoV-2 antibody titers and T-cell immune responses were measured in serum samples collected at several timepoints before and after vaccination. RESULTS: A total of 608 participants were included in the analysis. Antibody titers were elevated 3 weeks after vaccination and waned over the remainder of the study period. T-cell immune responses showed similar dynamics. Six participants without predisposing medical conditions seroconverted from negative to positive on the IgG assay for nucleocapsid proteins, indicating breakthrough SARS-CoV-2 infection. Five of the six breakthrough infections were asymptomatic. CONCLUSIONS: Both humoral and cellular immunity waned within 6 months after BNT162b2 vaccination. The incidence of asymptomatic breakthrough infection within 6 months after vaccination was approximately one percent. UMIN CLINICAL TRIALS REGISTRY ID: UMIN000043340.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Uwamino Y, Kurafuji T, Takato K, et al. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine. Vaccine. 2022. PMID: 35718591. doi:10.1016/j.vaccine.2022.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。